AUTOIMMUNE ENCEPHALITIS WITH GABA<sub>B</sub> ANTIBODIES, THYMOMA, AND GABA<sub>B</sub> RECEPTOR THYMIC EXPRESSION

Antibody-mediated autoimmune encephalopathies comprise a group of severe conditions with a varying degree of motor and cognitive symptoms that respond to immunotherapies. The associated antibodies are directed against intracellular targets, such as the classic paraneoplastic autoantigens Hu, Yo, Ri, CV2, Ma2/Ta, or the enzyme GAD, or against cell surface antigens such as receptors and ion channels.

A newly described pathogenic antibody in autoimmune encephalopathies is directed against the \( \gamma \)-aminobutyric acid receptor B (GABA<sub>B</sub>), a G-protein–coupled receptor. In 2 large series of more than 35 GABA<sub>B</sub>-seropositive patients, the most common symptoms were limbic encephalitis, seizures, ataxia, and opsoclonus myoclonus; only a single case presented with brainstem encephalitis. The GABA<sub>B</sub>-associated syndrome can be also paraneoplastic up to 35% of the cases, most often associated with small-cell lung cancer and quite often in conjunction with another paraneoplastic antibody.

We present a case of GABA<sub>B</sub>-associated autoimmune encephalopathy with brainstem manifestations, thymoma, and co-occurrence of anti-Hu and anti-CV2 antibodies. The main novelty of the case is GABA<sub>B</sub> expression in the thymus, implicating reactivity against the same antigen between thymus and brain.

**Case presentation.** A 25-year-old man was admitted for evaluation of recurrent episodes of vertigo, dizziness, persistent hiccups, nausea, and vomiting that started 3 months prior to admission. On admission he had normal cognitive functions, horizontal nystagmus intensified to the left, brisk tendon reflexes in the lower limbs, positive Romberg sign, and tongue myoclonus. After 1 week he developed right sixth nerve palsy with diplopia, and 2 weeks later he developed left third nerve palsy.

Routine blood tests were normal. CSF analysis yielded high protein (85 mg/dL), 10 white cells per mm\(^3\), and normal glucose. CSF viral serology and Gram stain were negative. Oligoclonal immunoglobulin G bands were detected. Visual evoked potentials, somatosensory evoked potentials, EMG, and serial EEGs were normal. A noncontrast CT scan and MRI of the brain and cervical spine were normal. A chest-abdominal CT revealed a mass in the anterior mediastinum suspicious for thymoma. A complete thymectomy was performed and pathology revealed a type B1 (lymphocyte-rich) thymoma.

His symptoms improved after surgery but worsened 2 weeks later, and he was started on oral methylprednisolone for 5 days. He again improved, but his symptoms reappeared 7 months later with the addition of excessive startle. Screening of serum for classic paraneoplastic autoantibodies by Western blot (Euroimmun, Lübeck, Germany) and autoimmune encephalitis autoantibodies by cell-based assays (Euroimmun) showed positivity for anti-Hu, anti-CV2, and anti-GABA<sub>B</sub> receptor but negativity for anti-Ri, anti-Yo, anti-Ma2/Ta, anti-amphiphysin, anti-LGI1, anti-CASPR2, anti-NMDAR, anti-GAD, anti-glycine receptor, anti-AQP4, anti-AChR (tested with the most sensitive radioimmunoassay), and anti-MuSK. Therefore, the diagnosis of paraneoplastic brainstem autoimmune encephalitis was established.

**Immunocytochemistry.** To probe for GABA<sub>B</sub> thymic expression, 5-μm tissue sections from the excised thymoma were incubated following deparaffinization with an antibody against GABA<sub>B</sub> (1:100 rabbit polyclonal; Abcam, Cambridge, United Kingdom) in combination with an antibody that detects epithelial cells (1:60 pan-cytokeratin mouse monoclonal; Dako, Glostrup, Denmark). For secondary detection, a goat-anti-rabbit Alexa Fluor-568 (1:200; Life Technologies) was used. Patient serum was applied in sections (1:20) following deparaffinization and antigen retrieval combined with the pan-cytokeratin mouse monoclonal; (Dako, Glostrup, Denmark). For secondary detection, a goat-anti-rabbit Alexa Fluor-568 (1:200; Life Technologies) was used. Patient serum was applied in sections (1:20) following deparaffinization and antigen retrieval combined with the pan-cytokeratin antibody. Secondary detection was performed with the combination of goat-anti-human Alexa Fluor-568 (1:200) and goat-anti-mouse Alexa Fluor-488 (1:200; Life Technologies) were used. Patient serum was applied to the tissue as controls in combination with the pan-cytokeratin antibodies. No nonspecific

---

**Notes**
staining was observed. The University of Athens Ethics Committee granted ethical approval and patient informed consent was received.

**Patient’s follow-up.** Because his symptomatology worsened, the patient underwent a 7-day course of plasmapheresis followed by 1 g of IV methylprednisolone for 5 days. All symptoms rapidly disappeared except for slight dizziness and vertigo in the supine position. He was discharged on methylprednisolone by mouth. Azathioprine was later added. Now, 18 months after his discharge, he remains stable.

**Discussion.** This case presents several novelties. It extends the clinical phenotype of GABA\_B receptor–associated encephalitis to include brainstem encephalitis. It is also the first case associated with thymoma and co-occurrence with 2 other paraneoplastic antibodies, namely anti-Hu and anti-CV2. Although these antibodies can coexist in some patients and anti-CV2–related encephalitis with thymoma has also been reported, CV2-positive patients do not develop brainstem signs. Their clinical symptomatology is different and includes cerebellar ataxia, chorea, uveo/retinal symptoms, and myasthenic syndrome.\(^6,7\) In our case, the rapid response to plasmapheresis after symptom reoccurrence strongly suggests (although does not prove) that the main causative factor was humoral immunity associated with GABA\_B antibodies rather than T-cell immunity implicated in CV2 and Hu paraneoplastic syndromes. The key role of GABA\_B is further highlighted by finding GABA\_B expression in the

---

**Figure 1** GABA\_B expression in the thymus

(A–C) Staining of thymus tissue with anti-cytokeratin (A) and anti-GABA\_B antibody (B, C double immunofluorescence). Cytokeratin-positive epithelial cells express GABA\_B receptor (arrows). In addition, GABA\_B is expressed in other cell types of the thymus, most likely T cells (arrowheads). (D–F) Staining of thymus tissue with anti-cytokeratin (D) and patient sera (E, F double immunofluorescence). Patient antibodies clearly co-localize with cytokeratin-positive epithelial cells. The pattern of staining and co-localization in these areas is identical to panels A, B, and C. Due to antibody combination and tissue availability restrictions, we were unable to triple stain for cytokeratin-GABA\_B serum. From our results it can be safely inferred that the GABA\_B serum autoantibodies bind GABA\_B that is expressed in thymic epithelial cells. GABA\_B = \(\gamma\)-aminobutyric acid receptor B.
thymomatous epithelial cells and the temporal association of improvement onset and thymectomy.

GABAB expression has not been previously demonstrated in a thymoma or in any of the tumors associated with GABAB-positive autoimmune encephalitis. It is likely that the demonstration of GABAB receptor expression in the thymic epithelial cells has triggered a pathogenetic mechanism of autoimmunization through reactivity with the same antigen in the thymus and brain.

*These authors contributed equally to this work.

From the Neuroimmunology Unit (H.A., S.A., M.C.D.), Department of Pathophysiology, and 1st Department of Neurology (M.C.D.), Faculty of Medicine, National and Kapodistrian University of Athens; and 3rd Department of Neurology (I.E.D., S.B.), Medical School, Aristotle University of Thessaloniki, Greece.

Author contributions: Dr. Alexopoulos, Dr. Baldantopoulou, Dr. Dagklis, Dr. Dalakas: study concept and design. Dr. Dagklis, Dr. Alexopoulos, Ms. Akrivou: acquisition of data. Dr. Alexopoulos, Ms. Akrivou, Dr. Dagklis: analysis and interpretation. Dr. Alexopoulos, Dr. Dagklis, Dr. Baldantopoulou, Dr. Dalakas: drafting and critical revision of the manuscript.

Study funding: No targeted funding reported.

Disclosure: H. Alexopoulos, I.E. Dagklis, and S. Akrivou report no disclosures. S. Bostantjopoulos has received funding for travel from Novartis and UCB. M.C. Dalakas is on the scientific advisory board for Novartis, Grifols, and Baxter; has received honoraria from Baxter, Novartis, Grifols, CSL, Octapharma, Dysimmune Diseases Foundation, and Therapath; is on the editorial board for Neurology, BMC Neurology, Neuropathology and Applied Neurobiology, Acta Neurologica Scandinavica, and Therapeutic Advances in Neurology; has consulted for Therapath, Grifols, Novartis, Baxter, Octapharma, and Dysimmune Diseases Foundation; is on the speakers' bureau for Talecris; and received support from Talecris, IVIG America, Biogen, Serono, Genzyme, Novartis, Teva, and CSL. Go to Neurology.org for full disclosures. The Article Processing Charge was paid by the Special Research Account, University of Athens.

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Received June 9, 2014. Accepted in final form September 9, 2014.

Correspondence to Dr. Dalakas: mdalakas@med.uoa.gr

Autoimmune encephalitis with GABA_β_ antibodies, thymoma, and GABA_β_ receptor thymic expression


*Neurol Neuroimmunol Neuroinflamm* 2014;1;
DOI 10.1212/NXI.0000000000000039

This information is current as of October 29, 2014

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://nn.neurology.org/content/1/4/e39.full.html">http://nn.neurology.org/content/1/4/e39.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Supplementary material can be found at: <a href="http://nn.neurology.org/content/suppl/2014/10/29/1.4.e39.DC1">http://nn.neurology.org/content/suppl/2014/10/29/1.4.e39.DC1</a></td>
</tr>
<tr>
<td>References</td>
<td>This article cites 7 articles, 1 of which you can access for free at: <a href="http://nn.neurology.org/content/1/4/e39.full.html##ref-list-1">http://nn.neurology.org/content/1/4/e39.full.html##ref-list-1</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://nn.neurology.org/misc/about.xhtml#permissions">http://nn.neurology.org/misc/about.xhtml#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://nn.neurology.org/misc/addir.xhtml#reprintsus">http://nn.neurology.org/misc/addir.xhtml#reprintsus</a></td>
</tr>
</tbody>
</table>

*Neurol Neuroimmunol Neuroinflamm* is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2014 American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.